A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients With Advanced Malignant Tumors

This is a Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

Study Overview

• Status: Recruiting
• Conditions: Advanced Malignant Tumors
• Intervention / Treatment: Drug: IAP0971

Detailed Description

The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa).First, the Phase Ia dose escalation will be carried out. After finishing the Phase 1a，the Phase Ib dose extension study can be carried out in the MTD dose which can be achieved from Phase 1a. After Phase Ia & Ib are completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.

• Study Type: Interventional
• Enrollment (Estimated): 140
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Minwei Manager; Phone Number: 18068131816; Email: shenminwei@sunho-bio.com

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200120
      • Recruiting
      • Shanghai East Hospital
      • Contact: Jin Li, master; Phone Number: +86-021-38804518; Email: lijin@csco.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

- 1. Age 18 to 80 years, male or female. 2. Patients with histologically or cytologically confirmed advanced or unresectable solid tumors or and relapsed and/or refractory non-Hodgkin's lymphoma, who have progressed on or have been intolerant to standard treatment, or for whom no standard treatment exists.

3. Dose Escalation Phase (Part A)：At least one evaluable tumor lesion per RECIST 1.1 (solid tumors) or Lugano 2014 (lymphomas).

Dose Expansion Phase (Part B)：At least one measurable tumor lesion per RECIST 1.1 (solid tumors) or Lugano 2014 (lymphomas).

4. Agree to provide previously stored tumor tissue specimens or perform biopsy to collect tumor lesion tissue and send it to the central laboratory for PD-L1 expression level detection.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. (see Appendix 3) 6. Adequate organ function: Hematological system (No blood transfusion or hematopoietic stimulating factor therapy within 14 days) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L White blood cell count (WBC) ≥ 3.0 × 109/L Platelets (PLT) ≥ 75 × 109/L Hemoglobin (Hb) ≥ 90 g/L Hepatic function Total bilirubin (TBIL) ≤ 3 × ULN Alanine aminotransferase (ALT) ≤ 3 × ULN; Aspartate aminotransferase (AST) ≤ 3 × ULN; Renal function Creatinine clearance (Ccr) (only calculated if creatinine > 3 × ULN) ≥ 50 mL/min (calculated according to Cockcroft-Gault formula, see Appendix 7 for formula) Coagulation function Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN 7. Expected survival time of more than 3 months. 8. Eligible patients of childbearing potential (men and women) must agree to use a reliable method of contraception (hormonal or barrier method or abstinence, etc.) with their partners during the trial and for at least 90 days after study drug administration; female patients of childbearing potential (see Appendix 8 for definition) must have a negative blood or urine pregnancy test 7 days before the first administration.

9. Subjects must be informed of the study prior to the trial and voluntarily sign a written informed consent form.

Exclusion Criteria:

- 1. Patients who have a severe hypersensitivity reaction to any monoclonal antibody (CTCAE 5.0 grade ≥ 3).

2. Patients who received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy, and other anti-tumor treatment within 4 weeks before the first administration, except for the following: Nitrosourea or mitomycin C was received within 6 weeks before the first administration; Oral fluoropyrimidines and small molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to the first administration.

Chinese proprietary medicines with anti-tumor indications were received within 2 weeks before the first administration.

3. Receipt of other non-marketed investigational drugs or treatments within 4 weeks before the first administration.

4. Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first administration, or require elective surgery during the trial.

5. Patients who have received systemic glucocorticoids (prednisone > 10 mg/day or equivalent doses of similar drugs) or other immunosuppressive agents within 14 days before the first administration; exclude the following conditions: topical, ophthalmic, intra-articular, intranasal or inhaled corticosteroid therapy; short-term use of glucocorticoid for preventive treatment (for example, prevention of contrast agent allergy).

6. Patients who have received immunomodulatory drugs within 14 days before the first administration, including but not limited to thymosin, interleukin-2, interferon, etc.

7. Patients who have received live attenuated vaccines within 4 weeks before the first administration.

8. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.

9. The adverse reactions caused by previous anti-tumor treatment have not recovered to CTCAE 5.0 grade ≤ 1 (except for toxicity without safety risk as judged by the investigator, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.).

10. Patients with active infection who need intravenous anti-infective therapy. 11. Patients with interstitial lung disease (except for radiation pulmonary fibrosis not requiring hormone therapy).

12. History of serious cardiovascular and cerebrovascular diseases, including but not limited to: Patients with severe cardiac rhythm or conduction abnormalities, such as arrhythmia requiring clinical intervention, second-degree to third-degree atrioventricular block; QT interval (QTcF) corrected by Fridericia's method > 470 ms (see Appendix 9 for calculation formula); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 and above cardiovascular and cerebrovascular events within 6 months prior to the first dose; Patients with heart failure with cardiac function class ≥ II according to New York Heart Association (NYHA) (see Appendix 4) or Left Ventricular Ejection Fraction (LVEF) < 50%; Clinically uncontrolled hypertension. 13. Patients who currently have active or have had autoimmune diseases that may have recurrence (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for clinically stable autoimmune thyroid diseases, type I Diabetics.

14. Patients who have received immunotherapy and developed irAE ≥3 or immune-related myocarditis ≥2.

15. Clinically uncontrolled effusion in the third space, which is not suitable for enrollment based on the investigator's judgment.

16. Known alcohol or drug dependence. 17. Patients with mental disorders or poor compliance. 18. Women who are pregnant or breastfeeding. 19. The subject has a history of other serious systemic diseases or other reasons that make the subject unsuitable for this clinical study in the opinion of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase Ia - Dose escalation; The goal of the Dose Escalation Phase (Part A) is to initially characterize the safety and tolerability of IAP0971, and more specifically to describe the DLTs for each dose level studied and to define the MTD based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.	Drug: IAP0971; IAP0971 should be subcutaneous injected，q2w
Experimental: Phase Ib - Dose extension; During the Dose Expansion Phase , patients will be enrolled to receive IAP0971 at the MTD established from the Dose Escalation Phase of the study.	Drug: IAP0971; IAP0971 should be subcutaneous injected，q2w
Experimental: Phase IIa - Clinical Exploratory Stage; After finishing Phase 1, invesigators will discuss with the sponsor about how to carry out the Phase IIa due to the results acheived from Phase I.	Drug: IAP0971; IAP0971 should be subcutaneous injected，q2w

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the safety of IAP0971 (Phase I)	MTD/RP2D; Incidence and frequency of DLT; AE, SAE occurrence and frequency (according to NCI CTCAE 5.0).	Through finishing Phase I, an average of 1 year
To evaluate the effectiveness of IAP0971 (Phase IIa)	Objective response rate(ORR)	Until disease progression, assessed up to 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK) Cmax（Phase I)	PK parameters Cmax following single dose	After single dose ,assessed up to 1 year
Pharmacokinetics (PK) Css,max（Phase I)	PK parameters Css,max following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) Css,min（Phase I)	PK parameters Css,min following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) Css,av（Phase I)	PK parameters Css,av following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) AUCss（Phase I)	PK parameters AUCss following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) CLss（Phase I)	PK parameters CLss following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) Vss（Phase I)	PK parameters Vss following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) R（Phase I)	PK parameters R following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) DF（Phase I)	PK parameters DF following multiple doses	After multiple doses ,assessed up to 1 year
Pharmacokinetics (PK) Tmax（Phase I)	PK parameters Tmax following single dose	After single dose ,assessed up to 1 year
Pharmacokinetics (PK) AUC0-t（Phase I)	PK parameters AUC0-t following single dose	After single dose ,assessed up to 1 year
Pharmacokinetics (PK) AUC0-∞（Phase I)	PK parameters AUC0-∞ following single dose	After single dose ,assessed up to 1 year
Pharmacokinetics (PK) CL（Phase I)	PK parameters CL following single dose	After single dose ,assessed up to 1 year
Pharmacokinetics (PK) Vd（Phase I)	PK parameters Vd following single dose	After single dose ,assessed up to 1 year
Pharmacokinetics (PK) t1/2（Phase I)	PK parameters t1/2 following single dose	After single dose ,assessed up to 1 year
Pharmacokinetics (PK) λz（Phase I)	PK parameters λz following single dose	After single dose ,assessed up to 1 year
To evaluate the immunogenicity of IAP0971 in patients with advanced malignant tumors (Phase I)	Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAb) against IAP0971	After finishing Phase I, an average of 1 year
To evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase I)	Overall survival (OS) according to RECIST 1.1 or Lugano 2014	After finishing Phase I, an average of 1 year
To evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase I)	Objective response rate (ORR) according to RECIST 1.1 or Lugano 2014	After finishing Phase I, an average of 1 year
To evaluate the immunogenicity of IAP0971 in patients with advanced malignant tumors (Phase IIa)	Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAb) against IAP0971	After finishing Phase IIa, assessed up to 3 years
o evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase IIa)	PFS according to RECIST 1.1 or Lugano 2014	After finishing Phase IIa, assessed up to 3 years
o evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase IIa)	DCR according to RECIST 1.1 or Lugano 2014	After finishing Phase IIa, assessed up to 3 years
o evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase IIa)	OS according to RECIST 1.1 or Lugano 2014	After finishing Phase IIa, assessed up to 3 years

Collaborators and Investigators

• Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.
• Investigators: Principal Investigator: Jin Li, M.D., Shanghai East Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 22, 2022
• Primary Completion (Estimated): May 30, 2024
• Study Completion (Estimated): November 30, 2024

Study Registration Dates

• First Submitted: May 19, 2022
• First Submitted That Met QC Criteria: May 24, 2022
• First Posted (Actual): May 31, 2022

Study Record Updates

• Last Update Posted (Actual): July 20, 2023
• Last Update Submitted That Met QC Criteria: July 18, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: PD1; IL15; Advanced Malignant Tumors
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: IAP0971-I/IIa

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No